GRIK2

Last updated
GRIK2
Protein GRIK2 PDB 1s50.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases GRIK2 , EAA4, GLR6, GLUK6, GLUR6, GluK2, MRT6, glutamate ionotropic receptor kainate type subunit 2, NEDLAS
External IDs OMIM: 138244 MGI: 95815 HomoloGene: 40717 GeneCards: GRIK2
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001166247
NM_021956
NM_175768

NM_001111268
NM_010349

RefSeq (protein)

NP_001159719
NP_068775
NP_786944

NP_001104738
NP_034479
NP_001345795

Location (UCSC) Chr 6: 100.96 – 102.08 Mb Chr 10: 49.09 – 49.79 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Glutamate ionotropic receptor kainate type subunit 2, also known as ionotropic glutamate receptor 6 or GluR6, is a protein that in humans is encoded by the GRIK2 (or GLUR6) gene. [5] [6] [7]

Contents

Function

This gene encodes a subunit of a kainate glutamate receptor. This receptor may have a role in synaptic plasticity, learning, and memory. It also may be involved in the transmission of visual information from the retina to the hypothalamus. The structure and function of the encoded protein is influenced by RNA editing. Alternatively spliced transcript variants encoding distinct isoforms have been described for this gene. [7] Recently, it has been discovered that this is a key protein, which enables mammals to feel cold sensations. [8]

Clinical significance

Homozygosity for a GRIK2 deletion-inversion mutation is associated with non-syndromic autosomal recessive mental retardation. [9]

Interactions

GRIK2 has been shown to interact with:

RNA Editing

Pre-mRNA for several neurotransmitter receptors and ion channels are substrates for ADARs, including AMPA receptor subunits (GluR2, GluR3, GluR4) and kainate receptor subunits (GluR5, GluR6). Glutamate-gated ion channels are made up of four subunits per channel, with each subunit contributing to the pore loop structure. The pore loop structure is similar to that found in K+ channels (e.g. the human Kv1.1 channel, whose pre-mRNA is also subject to A to I RNA editing). [17] [18] The diversity of ionotropic glutamate receptor subunits, as well as RNA splicing, is determined by RNA editing events of the individual subunits, explaining their extremely high diversity.

Type

The type of RNA editing that occurs in the pre-mRNA of GluR6 is Adenosine to Inosine (A to I) editing. [19]

A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs and deaminate them to inosine. Inosines are recognised as guanosine by the cell's translational machinery. There are three members of the ADAR family ADARs 1–3 with ADAR1 and ADAR2 being the only enzymatically active members. ADAR1 and ADAR2 are widely expressed in tissues, while ADAR3 is restricted to the brain, where it is though tot have a regulatory role. The double-stranded regions of RNA are formed by base-pairing between residues close to region of the editing site, with residues usually in a neighboring intron, though they can occasionally be located in an exonic sequence. The region that forms base pairs with the editing region is known as an Editing Complementary Sequence (ECS).

ADARs bind interact directly with the dsRNA substrate via their double-stranded RNA binding domains. If an editing site occurs within a coding sequence, the result could be a codon change. This can lead to translation of a protein isoform due to a change in its primary protein structure. Therefore, editing can also alter protein function. A to I editing occurs in a noncoding RNA sequences such as introns, untranslated regions (UTRs), LINEs, and SINEs (especially Alu repeats). The function of A to I editing in these regions is thought to involve creation of splice sites and retention of RNAs in the nucleus amongst others.

Location

The pre-mRNA of GLUR6 is edited at amino acid positions 567, 571, and 621. The Q/R position, which gets its name as editing results in an codon change from a glutamine (Q) codon (CAG) to an arginine (R) codon (CGG), is located in the "pore loop" of the second membrane domain (M2). The Q/R site of GluR6 pre-mRNA occurs in an asymmetrical loop of three exonic and four intronic nucleotides. The Q/R editing site is also observed in GluR2 and GluR5. The Q/R site is located in a homologous position in GluR2 and in GluR6. [20]

GluR-6 is also edited at I/V and Y/C sites, which are found in the first membrane domain (M1). At the I/V site, editing results in a codon change from (ATT) isoleucine (I) to (GTT) valine (V), while at the Y/C site, the codon change is from (TAC) tyrosine (Y) to (TGC) cysteine (C). [21]

The RNAfold program characterised a putative double-stranded RNA (dsRNA) conformation around the Q/R site of the GluR-6 pre-mRNA. This sequence is necessary for editing at the site to occur. The possible editing complementary sequence was observed from transcript analysis to be 1.9 kb downstream from the editing site within intron 12. [20] The ECS for the editing sites in M1 has yet to be identified but it is likely to occur at a considerable distance from the editing sites. [22]

Regulation

Editing of the Q/R site in GluR6 pre-mRNA has been demonstrated to be developmentally regulated in rats, ranging from 0% in rat embryo to 80% at birth. This is different from the AMPA receptor subunit GluR2, which is nearly 100% edited and is not developmentally regulated. [21] Significant amounts of both edited and non-edited forms of GluR6 transcripts are found in the adult brain. The receptor is 90% edited in all grey matter structures, while in white matter, the receptor is edited in just 10% of cases. Frequency increases from 0% in rat embryo to 85% in adult rat.

Consequences

Structure

The primary GluR6 transcripts can be edited in up to three positions. Editing at each of the three positions affects Ca2+ permeability of the channel. [23]

Function

Editing plays a role in the electrophysiology of the channel. Editing at the Q/R site has been deemed to be nonessential in GluR6. [24] It has been reported that the unedited version of GluR6 functions in the regulation of synaptic plasticity. The edited version is thought to inhibit synaptic plasticity and reduce seizure susceptibility. [23] Mice lacking the Q/R site exhibit increased long term potentiation and are more susceptible to kainate induced seizures. The number of seizures is inversely correlated with the amount of RNA editing. Human GluR6 pre-mRNA editing is increased during seizures, possibly as an adaptive mechanism. [25] [26]

Up to 8 different protein isoforms can occur as a result of different combinations of editing at the three sites, giving rise to receptor variants with differing kinetics. The effect of Q/R site editing on calcium permeability appears to be dependent on editing of the I/V and Y/C sites. When both sites in TM1 (I/V and Y/C) are edited, Q/R site editing is required for calcium permeability. On the contrary, when neither the I/V nor the Y/C site is edited, receptors demonstrate high calcium permeability regardless of Q/R site editing. The co-assembly of these two isoforms generate receptors with reduced calcium permeability. [23]

RNA editing of the Q/R site can affect inhibition of the channel by membrane fatty acids such as arachidonic acid and docosahexaenoic acid [27] For Kainate receptors with only edited isforms, these are strongly inhibited by these fatty acids, however inclusion of just one non-edited subunit is enough to abolish this effect. [27]

Dysregulation

Kainate-induced seizures in mice are used as a model of temporal lobe epilepsy in humans. Despite mice deficient in editing at the Q/R site of GluR6 showing increased seizure susceptibility, tissue analysis of human epilepsy patients did not show reduced editing at this site. [24] [28] [29] [30]

See also

Related Research Articles

<span class="mw-page-title-main">AMPA receptor</span> Transmembrane protein family

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (also known as AMPA receptor, AMPAR, or quisqualate receptor) is an ionotropic transmembrane receptor for glutamate (iGluR) and predominantly Na+ ion channel that mediates fast synaptic transmission in the central nervous system (CNS). It has been traditionally classified as a non-NMDA-type receptor, along with the kainate receptor. Its name is derived from its ability to be activated by the artificial glutamate analog AMPA. The receptor was first named the "quisqualate receptor" by Watkins and colleagues after a naturally occurring agonist quisqualate and was only later given the label "AMPA receptor" after the selective agonist developed by Tage Honore and colleagues at the Royal Danish School of Pharmacy in Copenhagen. The GRIA2-encoded AMPA receptor ligand binding core (GluA2 LBD) was the first glutamate receptor ion channel domain to be crystallized.

<span class="mw-page-title-main">Kainate receptor</span> Class of ionotropic glutamate receptors

Kainate receptors, or kainic acid receptors (KARs), are ionotropic receptors that respond to the neurotransmitter glutamate. They were first identified as a distinct receptor type through their selective activation by the agonist kainate, a drug first isolated from the algae Digenea simplex. They have been traditionally classified as a non-NMDA-type receptor, along with the AMPA receptor. KARs are less understood than AMPA and NMDA receptors, the other ionotropic glutamate receptors. Postsynaptic kainate receptors are involved in excitatory neurotransmission. Presynaptic kainate receptors have been implicated in inhibitory neurotransmission by modulating release of the inhibitory neurotransmitter GABA through a presynaptic mechanism.

<span class="mw-page-title-main">Glutamate receptor</span> Cell-surface proteins that bind glutamate and trigger changes which influence the behavior of cells

Glutamate receptors are synaptic and non synaptic receptors located primarily on the membranes of neuronal and glial cells. Glutamate is abundant in the human body, but particularly in the nervous system and especially prominent in the human brain where it is the body's most prominent neurotransmitter, the brain's main excitatory neurotransmitter, and also the precursor for GABA, the brain's main inhibitory neurotransmitter. Glutamate receptors are responsible for the glutamate-mediated postsynaptic excitation of neural cells, and are important for neural communication, memory formation, learning, and regulation.

<span class="mw-page-title-main">Ionotropic glutamate receptor</span> Ligand-gated ion channels

Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that are activated by the neurotransmitter glutamate. They mediate the majority of excitatory synaptic transmission throughout the central nervous system and are key players in synaptic plasticity, which is important for learning and memory. iGluRs have been divided into four subtypes on the basis of their ligand binding properties (pharmacology) and sequence similarity: AMPA receptors, kainate receptors, NMDA receptors and delta receptors.

<span class="mw-page-title-main">GRIA3</span> Protein-coding gene in humans

Glutamate receptor 3 is a protein that in humans is encoded by the GRIA3 gene.

<span class="mw-page-title-main">Metabotropic glutamate receptor 6</span> Mammalian protein found in humans

Glutamate receptor, metabotropic 6, also known as GRM6 or mGluR6, is a protein which in humans is encoded by the GRM6 gene.

<span class="mw-page-title-main">GRIN2A</span> Protein-coding gene in the species Homo sapiens

Glutamate [NMDA] receptor subunit epsilon-1 is a protein that in humans is encoded by the GRIN2A gene. With 1464 amino acids, the canonical GluN2A subunit isoform is large. GluN2A-short isoforms specific to primates can be produced by alternative splicing and contain 1281 amino acids.

<span class="mw-page-title-main">GRIN1</span> Protein-coding gene in the species Homo sapiens

Glutamate [NMDA] receptor subunit zeta-1 is a protein that in humans is encoded by the GRIN1 gene.

<span class="mw-page-title-main">GRIA1</span> Mammalian protein found in Homo sapiens

Glutamate receptor 1 is a protein that in humans is encoded by the GRIA1 gene.

<span class="mw-page-title-main">GRIA2</span> Mammalian protein found in Homo sapiens

Glutamate ionotropic receptor AMPA type subunit 2 is a protein that in humans is encoded by the GRIA2 gene and it is a subunit found in the AMPA receptors.

<span class="mw-page-title-main">GRIK1</span> Protein-coding gene in the species Homo sapiens

Glutamate receptor, ionotropic, kainate 1, also known as GRIK1, is a protein that in humans is encoded by the GRIK1 gene.

<span class="mw-page-title-main">GRIA4</span>

Glutamate receptor 4 is a protein that in humans is encoded by the GRIA4 gene.

<span class="mw-page-title-main">GRID2</span> Protein-coding gene in the species Homo sapiens

Glutamate receptor, ionotropic, delta 2, also known as GluD2, GluRδ2, or δ2, is a protein that in humans is encoded by the GRID2 gene. This protein together with GluD1 belongs to the delta receptor subtype of ionotropic glutamate receptors. They possess 14–24% sequence homology with AMPA, kainate, and NMDA subunits, but, despite their name, do not actually bind glutamate or various other glutamate agonists.

<span class="mw-page-title-main">GRIK3</span> Protein-coding gene in the species Homo sapiens

Glutamate receptor, ionotropic kainate 3 is a protein that in humans is encoded by the GRIK3 gene.

<span class="mw-page-title-main">GRIK5</span> Protein-coding gene in the species Homo sapiens

Glutamate receptor, ionotropic kainate 5 is a protein that in humans is encoded by the GRIK5 gene.

<span class="mw-page-title-main">GRID1</span> Protein-coding gene in the species Homo sapiens

Glutamate receptor delta-1 subunit also known as GluD1 or GluRδ1 is a transmembrane protein encoded by the GRID1 gene. A C-terminal GluD1 splicing isoform has been described based on mRNA analysis.

<span class="mw-page-title-main">GRIK4</span> Protein-coding gene in the species Homo sapiens

GRIK4 is a kainate receptor subtype belonging to the family of ligand-gated ion channels which is encoded by the GRIK4 gene.

Within the science of molecular biology and cell biology, for human genetics, the GRIA2 gene is located on chromosome 4q32-q33. The gene product is the ionotropic AMPA glutamate receptor 2. The protein belongs to a family of ligand-activated glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA). Glutamate receptors function as the main excitatory neurotransmitter at many synapses in the central nervous system. L-glutamate, an excitatory neurotransmitter, binds to the Gria2 resulting in a conformational change. This leads to the opening of the channel converting the chemical signal to an electrical impulse. AMPA receptors (AMPAR) are composed of four subunits, designated as GluR1 (GRIA1), GluR2 (GRIA2), GluR3 (GRIA3), and GluR4(GRIA4) which combine to form tetramers. They are usually heterotrimeric but can be homodimeric. Each AMPAR has four sites to which an agonist can bind, one for each subunit.[5]

<span class="mw-page-title-main">Glutamate (neurotransmitter)</span> Anion of glutamic acid in its role as a neurotransmitter

In neuroscience, glutamate is the anion of glutamic acid in its role as a neurotransmitter. It is by a wide margin the most abundant excitatory neurotransmitter in the vertebrate nervous system. It is used by every major excitatory function in the vertebrate brain, accounting in total for well over 90% of the synaptic connections in the human brain. It also serves as the primary neurotransmitter for some localized brain regions, such as cerebellum granule cells.

<span class="mw-page-title-main">Willardiine</span> Chemical compound

Willardiine (correctly spelled with two successive i's) or (S)-1-(2-amino-2-carboxyethyl)pyrimidine-2,4-dione is a chemical compound that occurs naturally in the seeds of Mariosousa willardiana and Acacia sensu lato. The seedlings of these plants contain enzymes capable of complex chemical substitutions that result in the formation of free amino acids (See:#Synthesis). Willardiine is frequently studied for its function in higher level plants. Additionally, many derivates of willardiine are researched for their potential in pharmaceutical development. Willardiine was first discovered in 1959 by R. Gmelin, when he isolated several free, non-protein amino acids from Acacia willardiana (another name for Mariosousa willardiana) when he was studying how these families of plants synthesize uracilyalanines. A related compound, Isowillardiine, was concurrently isolated by a different group, and it was discovered that the two compounds had different structural and functional properties. Subsequent research on willardiine has focused on the functional significance of different substitutions at the nitrogen group and the development of analogs of willardiine with different pharmacokinetic properties. In general, Willardiine is the one of the first compounds studied in which slight changes to molecular structure result in compounds with significantly different pharmacokinetic properties.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000164418 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000056073 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. HGNC. "Symbol Report: GRIK2" . Retrieved 29 December 2017.
  6. Paschen W, Blackstone CD, Huganir RL, Ross CA (Aug 1994). "Human GluR6 kainate receptor (GRIK2): molecular cloning, expression, polymorphism, and chromosomal assignment". Genomics. 20 (3): 435–40. doi: 10.1006/geno.1994.1198 . PMID   8034316.
  7. 1 2 "Entrez Gene: GRIK2 glutamate receptor, ionotropic, kainate 2".
  8. Sherburne, Morgan (11 March 2024). "Unlocking the Chill: Protein Behind Cold Sensation Found".
  9. Motazacker MM, Rost BR, Hucho T, Garshasbi M, Kahrizi K, Ullmann R, Abedini SS, Nieh SE, Amini SH, Goswami C, Tzschach A, Jensen LR, Schmitz D, Ropers HH, Najmabadi H, Kuss AW (October 2007). "A defect in the ionotropic glutamate receptor 6 gene (GRIK2) is associated with autosomal recessive mental retardation". Am. J. Hum. Genet. 81 (4): 792–8. doi:10.1086/521275. PMC   2227928 . PMID   17847003.
  10. 1 2 Mehta S, Wu H, Garner CC, Marshall J (May 2001). "Molecular mechanisms regulating the differential association of kainate receptor subunits with SAP90/PSD-95 and SAP97". J. Biol. Chem. 276 (19): 16092–9. doi: 10.1074/jbc.M100643200 . PMID   11279111.
  11. 1 2 Garcia EP, Mehta S, Blair LA, Wells DG, Shang J, Fukushima T, Fallon JR, Garner CC, Marshall J (Oct 1998). "SAP90 binds and clusters kainate receptors causing incomplete desensitization". Neuron. 21 (4): 727–39. doi: 10.1016/s0896-6273(00)80590-5 . PMID   9808460. S2CID   18723258.
  12. 1 2 3 4 Hirbec H, Francis JC, Lauri SE, Braithwaite SP, Coussen F, Mulle C, Dev KK, Coutinho V, Meyer G, Isaac JT, Collingridge GL, Henley JM, Couthino V (Feb 2003). "Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP". Neuron. 37 (4): 625–38. doi:10.1016/s0896-6273(02)01191-1. PMC   3314502 . PMID   12597860.
  13. Kohda K, Kamiya Y, Matsuda S, Kato K, Umemori H, Yuzaki M (Jan 2003). "Heteromer formation of delta2 glutamate receptors with AMPA or kainate receptors". Brain Res. Mol. Brain Res. 110 (1): 27–37. doi:10.1016/s0169-328x(02)00561-2. PMID   12573530.
  14. Wenthold RJ, Trumpy VA, Zhu WS, Petralia RS (Jan 1994). "Biochemical and assembly properties of GluR6 and KA2, two members of the kainate receptor family, determined with subunit-specific antibodies". J. Biol. Chem. 269 (2): 1332–9. doi: 10.1016/S0021-9258(17)42262-9 . PMID   8288598.
  15. Ripellino JA, Neve RL, Howe JR (Jan 1998). "Expression and heteromeric interactions of non-N-methyl-D-aspartate glutamate receptor subunits in the developing and adult cerebellum". Neuroscience. 82 (2): 485–97. doi: 10.1016/s0306-4522(97)00296-0 . PMID   9466455. S2CID   23219004.
  16. 1 2 Hirbec H, Perestenko O, Nishimune A, Meyer G, Nakanishi S, Henley JM, Dev KK (May 2002). "The PDZ proteins PICK1, GRIP, and syntenin bind multiple glutamate receptor subtypes. Analysis of PDZ binding motifs". J. Biol. Chem. 277 (18): 15221–4. doi: 10.1074/jbc.C200112200 . hdl: 2262/89271 . PMID   11891216.
  17. Seeburg PH, Single F, Kuner T, Higuchi M, Sprengel R (July 2001). "Genetic manipulation of key determinants of ion flow in glutamate receptor channels in the mouse". Brain Res. 907 (1–2): 233–43. doi:10.1016/S0006-8993(01)02445-3. PMID   11430906. S2CID   11969068.
  18. Bhalla T, Rosenthal JJ, Holmgren M, Reenan R (October 2004). "Control of human potassium channel inactivation by editing of a small mRNA hairpin". Nat. Struct. Mol. Biol. 11 (10): 950–6. doi:10.1038/nsmb825. PMID   15361858. S2CID   34081059.
  19. 52. Seeburg PH, Higuchi M, Sprengel R. Brain Res Brain Res Rev. 1998;26:217–29.
  20. 1 2 Sommer B, Köhler M, Sprengel R, Seeburg PH (October 1991). "RNA editing in brain controls a determinant of ion flow in glutamate-gated channels". Cell . 67 (1): 11–9. doi:10.1016/0092-8674(91)90568-J. PMID   1717158. S2CID   22029384.
  21. 1 2 Bernard A, Khrestchatisky M (May 1994). "Assessing the extent of RNA editing in the TMII regions of GluR5 and GluR6 kainate receptors during rat brain development". J. Neurochem. 62 (5): 2057–60. doi:10.1046/j.1471-4159.1994.62052057.x. PMID   7512622. S2CID   27091741.
  22. Niswender CM (September 1998). "Recent advances in mammalian RNA editing". Cell. Mol. Life Sci. 54 (9): 946–64. doi:10.1007/s000180050225. PMID   9791538. S2CID   20556833.
  23. 1 2 3 Köhler M, Burnashev N, Sakmann B, Seeburg PH (March 1993). "Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing". Neuron . 10 (3): 491–500. doi:10.1016/0896-6273(93)90336-P. PMID   7681676. S2CID   39976579.
  24. 1 2 Vissel B, Royle GA, Christie BR, Schiffer HH, Ghetti A, Tritto T, Perez-Otano I, Radcliffe RA, Seamans J, Sejnowski T, Wehner JM, Collins AC, O'Gorman S, Heinemann SF (January 2001). "The role of RNA editing of kainate receptors in synaptic plasticity and seizures". Neuron . 29 (1): 217–27. doi: 10.1016/S0896-6273(01)00192-1 . PMID   11182093. S2CID   7976952.
  25. Bernard A, Ferhat L, Dessi F, Charton G, Represa A, Ben-Ari Y, Khrestchatisky M (February 1999). "Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation". Eur. J. Neurosci. 11 (2): 604–16. doi:10.1046/j.1460-9568.1999.00479.x. PMID   10051761. S2CID   7866926.
  26. Grigorenko EV, Bell WL, Glazier S, Pons T, Deadwyler S (July 1998). "Editing status at the Q/R site of the GluR2 and GluR6 glutamate receptor subunits in the surgically excised hippocampus of patients with refractory epilepsy". NeuroReport . 9 (10): 2219–24. doi:10.1097/00001756-199807130-00013. PMID   9694203. S2CID   28692872.
  27. 1 2 Wilding TJ, Fulling E, Zhou Y, Huettner JE (July 2008). "Amino acid substitutions in the pore helix of GluR6 control inhibition by membrane fatty acids". J. Gen. Physiol. 132 (1): 85–99. doi:10.1085/jgp.200810009. PMC   2442176 . PMID   18562501.
  28. Nadler JV (November 1981). "Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy". Life Sci. 29 (20): 2031–42. doi:10.1016/0024-3205(81)90659-7. PMID   7031398.
  29. Ben-Ari Y (February 1985). "Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy". Neuroscience . 14 (2): 375–403. doi:10.1016/0306-4522(85)90299-4. PMID   2859548. S2CID   33597110.
  30. Kortenbruck G, Berger E, Speckmann EJ, Musshoff U (June 2001). "RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients". Neurobiol. Dis. 8 (3): 459–68. doi:10.1006/nbdi.2001.0394. PMID   11442354. S2CID   33605674.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.